Trial
NCT04274933
A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
AbbVie
Collaborators
—
Condition
Breast Cancer
Intervention
Venetoclax
Why stopped
Company Decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-10-29